Page results
-
This page is for patients who have been referred on a suspected cancer pathway.
-
Outcome of National Institute for Health and Care Excellence (NICE) Technology Appraisal for Exagamglogene autotemcel (Exa-cel) for treating transfusion- dependent beta thalassaemia [ID4015] in individuals 12 years and over.
-
Pfizer Limited, in agreement with the Medicines Healthcare products Regulatory Agency (MHRA), has withdrawn the product, while a review of the benefits and risks is carried out.
-
A smartphone app that identifies severe neonatal jaundice could provide a cheaper alternative to expensive screening procedures, according to a study by UCLH, UCL and the University of Ghana.
-
UCLH has recruited the first European participant to a trial looking at treating non-hospitalised Covid-19 patients with the drug remdesivir.
-
A major new consortium led by UCLH and UCL has been awarded £6.8 million by the National Institute of Health Research to conduct the largest clinical study of long COVID over the next two years.
-
This page provides information about the WEB device and how it is used to treat cerebral (brain) aneurysms
-
A second mass vaccination event will be held over four days this month at Emirates Stadium in a bid to give thousands more people the chance to have their first or second dose of the Pfizer Covid-19 vaccine.
-
One of our patients who is recovering from COVID-19 has been appearing across national media as she recounts her story and thanks the staff who saved her life.
-
UCLH is managing one of the three cancer hubs across London, so that during the COVID-19 coronavirus pandemic cancer surgery is available for patients with the most immediate needs.
File results
-
FOI/2024/0489 - Late starts for elective theatre sessions
-
FOI/2024/0488 - Emergency Preparedness, Resilience and Response Framework (EPRR) cycle of preparedness/ exercise dates
-
FOI/2024/0480 - Freedom of Information (FOI) requests 2020/21-2023/24
-
FOI/2024/0349 - Trust's operations and tele reporting services/ outsourced and insourced
-
FOI/2024/0354 - Staff details for estates and facilities
-
FOI/2024/0473 - Elective operations cancelled for non-clinical reasons 2023/24
-
FOI/2024/0478 - Elective operations cancelled for non-clinical reasons 2021/22-2023/24
-
FOI/2024/0479 - Applications or systems deployed on Microsoft Azure Cloud
-
FOI/2024/0368 - Treatment in renal cell carcinoma
-
FOI/2024/0486 - Diagnostic tests for both point of care testing and laboratory